IceCure Medical (ICCM) shareholders approve agenda item after adjourned meeting

Rhea-AI Filing Summary

IceCure Medical Ltd. held a Special General Meeting of Shareholders on May 11, 2026. The meeting was initially adjourned at 5:00 p.m. Israel time because there was no quorum, but it reconvened at 6:30 p.m., when a quorum was present.

At the adjourned meeting, shareholders voted on and approved the single agenda item described in the company’s proxy statement filed on April 22, 2026. This report is incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8.

Key Figures

Meeting date: May 11, 2026 Initial meeting time: 5:00 p.m. Israel time Adjourned meeting time: 6:30 p.m. Israel time +2 more

5 metrics

Meeting date May 11, 2026 Special General Meeting of Shareholders

Initial meeting time 5:00 p.m. Israel time Meeting adjourned due to lack of quorum

Adjourned meeting time 6:30 p.m. Israel time Meeting reconvened and quorum present

Form F-3 file numbers 333-258660, 333-290046 Registration statements incorporating this report

Form S-8 registration numbers 333-270982, 333-264578, 333-262620, 333-281587 Registration statements incorporating this report

Key Terms

Special General Meeting of Shareholders, quorum, Proxy Statement, Registration Statements on Form F-3, +1 more

5 terms

Special General Meeting of Shareholders financial

"On May 11, 2026, IceCure Medical Ltd. convened a Special General Meeting of Shareholders"

quorum financial

"The Meeting was initially adjourned due to there not being a required quorum present"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

Proxy Statement financial

"the agenda item that was described in the Company’s proxy statement for the Meeting"

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

Registration Statements on Form F-3 regulatory

"incorporated by reference into the Company’s Registration Statements on Form F-3"

Form S-8 regulatory

"and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620, and 333-281587)"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026 (Report No. 2)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

CONTENTS

On May 11, 2026, IceCure Medical Ltd. (the “Company”) convened a Special General Meeting of Shareholders (the “Meeting”).

The Meeting was initially adjourned due to there not being a required quorum present to open and conduct it at the initial time of 5:00 p.m. (Israel time). However, the adjourned Meeting was eventually held at 6:30 p.m. (Israel time). At the adjourned Meeting, a quorum was present and the shareholders of the Company voted upon and approved the agenda item that was described in the Company’s proxy statement for the Meeting, which is included in Exhibit 99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission (“SEC”) on April 22, 2026 (the “Proxy Statement”).

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-258660 and 333-290046) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620, and 333-281587), filed with the SEC, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IceCure Medical Ltd.
Date: May 11, 2026	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

2

FAQ

What did IceCure Medical (ICCM) report in its May 2026 Form 6-K?

IceCure reported that its May 11, 2026 Special General Meeting of Shareholders ultimately achieved a quorum and approved the agenda item described in the April 22, 2026 proxy statement, and that this report is incorporated into its existing F-3 and S-8 registration statements.

Why was IceCure Medical’s May 11, 2026 shareholder meeting initially adjourned?

The meeting was adjourned at 5:00 p.m. Israel time because there was no required quorum to open and conduct it. It later reconvened at 6:30 p.m. the same day, when a quorum was present and business could proceed.

What was approved at IceCure Medical’s Special General Meeting on May 11, 2026?

Shareholders approved the agenda item that was described in IceCure Medical’s proxy statement furnished to the SEC on April 22, 2026. The Form 6-K notes the approval but refers investors to that proxy statement for the detailed description.

How does this IceCure Medical (ICCM) 6-K affect existing registration statements?

The Form 6-K is incorporated by reference into IceCure’s Form F-3 registration statements and multiple Form S-8 registration statements. This means the information in the report becomes part of those registration documents from the submission date onward.

Which SEC registration statements does IceCure’s May 2026 6-K update?

The report is incorporated into IceCure’s Form F-3 registration statements with file numbers 333-258660 and 333-290046, and its Form S-8 registration statements with numbers 333-270982, 333-264578, 333-262620, and 333-281587, making the 6-K information part of those filings.